<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2500-5006</journal-id>
<journal-title><![CDATA[Revista Colombiana de Nefrología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. colom. nefrol.]]></abbrev-journal-title>
<issn>2500-5006</issn>
<publisher>
<publisher-name><![CDATA[Asociación Colombiana de Nefrología e Hipertensión Arterial]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2500-50062025000100014</article-id>
<article-id pub-id-type="doi">10.22265/acnef.12.1.801</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Consenso colombiano sobre la poliquistosis renal autosómica dominante]]></article-title>
<article-title xml:lang="en"><![CDATA[Colombian consensus on autosomal dominant polycystic kidney disease]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Roncallo]]></surname>
<given-names><![CDATA[Angelica]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aguirre]]></surname>
<given-names><![CDATA[Marcelo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A4"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Conde Manotas]]></surname>
<given-names><![CDATA[Juan Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gallón Blandón]]></surname>
<given-names><![CDATA[Paula Andrea]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lopera]]></surname>
<given-names><![CDATA[Mauricio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[José Gabriel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mantilla]]></surname>
<given-names><![CDATA[Andrea]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[Theo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Olivares]]></surname>
<given-names><![CDATA[Orlando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A0"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Restrepo-Valencia]]></surname>
<given-names><![CDATA[Cesar Augusto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A1"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Wassermann]]></surname>
<given-names><![CDATA[Alfredo Osvaldo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bermon]]></surname>
<given-names><![CDATA[Anderson]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Barros]]></surname>
<given-names><![CDATA[Luis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A4"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Asociación Colombiana de Nefrología e Hipertensión Arterial  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Comité de Nefropatías Hereditarias y Enfermedades Huérfanas  ]]></institution>
<addr-line><![CDATA[Barranquilla ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Sociedad Latinoamericana de Nefrología e Hipertensión  ]]></institution>
<addr-line><![CDATA[Panamá ]]></addr-line>
<country>Panamá</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Centro Médico Nefrochocó  ]]></institution>
<addr-line><![CDATA[Quibdó ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Clínica Victoriana  ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Hospital Pablo Tobón Uribe  ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af7">
<institution><![CDATA[,Clínica Las Vegas  ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af8">
<institution><![CDATA[,Hospital Universitario San José de Popayán  ]]></institution>
<addr-line><![CDATA[Popayán ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af9">
<institution><![CDATA[,Hospital San José  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="A10">
<institution><![CDATA[,Fresenius Medical Care  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="A11">
<institution><![CDATA[,Universidad de Caldas  ]]></institution>
<addr-line><![CDATA[Manizales ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="A12">
<institution><![CDATA[,Comité de Hipertensión Arterial  ]]></institution>
<addr-line><![CDATA[Buenos Aires ]]></addr-line>
<country>Argentina</country>
</aff>
<aff id="A13">
<institution><![CDATA[,Fundación Cardiovascular de Colombia  ]]></institution>
<addr-line><![CDATA[Bucaramanga ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="A14">
<institution><![CDATA[,NefroCaribe IPS  ]]></institution>
<addr-line><![CDATA[Barranquilla ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2025</year>
</pub-date>
<volume>12</volume>
<numero>1</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S2500-50062025000100014&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S2500-50062025000100014&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S2500-50062025000100014&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Contexto: La poliquistosis renal autosómica dominante (PQRAD) es la causa más frecuente de nefropatía hereditaria en el adulto y de enfermedad renal crónica estadio 5 de origen genético, además, es una enfermedad heterogénea con una variabilidad fenotípica con relación a la progresión, por lo que es necesario establecer todas las medidas encaminadas a enlentecer la progresión de la enfermedad renal.  Objetivo: Generar recomendaciones basadas en la evidencia para el diagnóstico, seguimiento y tratamiento del paciente con PQRAD, definiendo los pacientes con rápida progresión de la enfermedad, guiar el tratamiento general y específico con el agente tolvaptán, y establecer recomendaciones para el acceso a terapias de reemplazo renal, incluido el trasplante, mediante un consenso de expertos._  Metodología: A partir de la formulación de preguntas de investigación pragmáticas relacionadas con la PQRAD, se realiza la búsqueda de evidencia en las bases de datos Pubmed, Scopus y Ovid en el periodo de enero del 2012 a julio del 2023. Los artículos se seleccionaron por medio de una revisión sistemática y a través de la metodología de consenso Delphi modificado. Luego, se aplicó la escala Oxford para cuantificar el nivel de evidencia del total de artículos científicos seleccionados. Todas las recomendaciones finales fueron categorizadas por grado según la clasificación de las guías NHS.  Resultados: Se formularon en total 18 recomendaciones para el diagnóstico, tratamiento y seguimiento de la PQRAD, participaron un panel de 10 expertos temáticos, 1 experto metodológico y 2 revisores externos de forma activa para la elaboración del consenso.  Conclusiones: Las recomendaciones basadas en evidencia y experticia clínica adaptadas al contexto colombiano permitirán orientar de manera estandarizada, a nivel nacional y regional, el diagnóstico y el tratamiento de pacientes con PQRAD y orientar sobre el uso y aplicación de tolvaptán.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common cause of inherited adult nephropathy and stage 5 chronic kidney disease of genetic origin, it is a heterogeneous disease with phenotypic variability in relation to progression. All measures aimed at slowing the progression of renal disease should be established.  Purpose: To generate evidence-based recommendations for the diagnosis, follow-up and treatment of patients with ADPKD, defining patients with rapid disease progression, guide general and specific treatment with the agent tolvaptan, establish recommendations for access to renal replacement therapies including transplantation, through an expert consensus.  Methodology: Based on the formulation of pragmatic research questions related to ADPKD, a search for evidence was conducted in Pubmed, Scopus and Ovid between January 2012 and July 2023. The articles were selected by means of a systematic review and through the modified Delphi consensus methodology. The Oxford scale was applied to quantify the level of evidence of the total selected scientific articles. All final recommendations were categorised by grade according to the NHS guidelines classification.  Results: A total of 18 recommendations were formulated for the diagnosis, treatment and follow-up of ADPKD. A panel of 10 thematic experts, a methodological expert and 2 external reviewers actively participated in the elaboration of the consensus.  Conclusions: The recommendations based on evidence and clinical expertise adapted to the Colombian context will allow standardised guidance at national and regional level, the diagnosis and treatment of patients with ADPKD and provide guidance on the use and application of tolvaptan.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[poliquistosis renal autosómica dominante]]></kwd>
<kwd lng="es"><![CDATA[tolvaptán]]></kwd>
<kwd lng="es"><![CDATA[enfermedad renal]]></kwd>
<kwd lng="es"><![CDATA[quiste renal]]></kwd>
<kwd lng="es"><![CDATA[hipertensión arterial]]></kwd>
<kwd lng="es"><![CDATA[insuficiencia renal crónica]]></kwd>
<kwd lng="en"><![CDATA[Polycystic Kidney]]></kwd>
<kwd lng="en"><![CDATA[Autosomal Dominant]]></kwd>
<kwd lng="en"><![CDATA[tolvaptan]]></kwd>
<kwd lng="en"><![CDATA[Renal Disease]]></kwd>
<kwd lng="en"><![CDATA[Kidney Diseases]]></kwd>
<kwd lng="en"><![CDATA[Cystic]]></kwd>
<kwd lng="en"><![CDATA[hypertension]]></kwd>
<kwd lng="en"><![CDATA[Renal Insufficiency]]></kwd>
<kwd lng="en"><![CDATA[Chronic]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>[1]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saini]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Saini]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autosomal dominant polycystic kidney disease and pioglitazone for its therapy: a comprehensive review with an emphasis on the molecular pathogenesis and pharmacological aspects]]></article-title>
<source><![CDATA[Mol Med]]></source>
<year>2020</year>
<volume>26</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>128</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>[2]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McEwan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bennett Wilton]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ong]]></surname>
<given-names><![CDATA[ACM]]></given-names>
</name>
<name>
<surname><![CDATA[0rskov]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Sandford]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Scolari]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): The ADPKD Outcomes Model]]></article-title>
<source><![CDATA[BMC Nephrol]]></source>
<year>2018</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>37</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>[3]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[AB.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Best practices care of patients with autosomal dominant polycystic kidney disease in BC's Kidney Care Clinics]]></article-title>
<source><![CDATA[Journal of Nephrology]]></source>
<year>2019</year>
<volume>25</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>123-35</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>[4]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ars]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bernis]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fraga]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Furlano]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Martins]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consensus document on autosomal dominant polycystic kindey disease from the Spanish Working Group on Inherited Kindey Diseases. Review 2020]]></article-title>
<source><![CDATA[Nefrología]]></source>
<year>2022</year>
<volume>42</volume>
<numero>4</numero>
<edition>Engl</edition>
<issue>4</issue>
<page-range>367-89</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>[5]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[WB]]></given-names>
</name>
<name>
<surname><![CDATA[Xiao]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[YQ]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[XM]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[QJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Novel mutations of PKD genes in Chinese patients suffering from autosomal dominant polycystic kidney disease and seeking assisted reproduction]]></article-title>
<source><![CDATA[BMC Med Genet]]></source>
<year>2018</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>186</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>[6]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oh]]></surname>
<given-names><![CDATA[YK]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Ryu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[YC]]></given-names>
</name>
<name>
<surname><![CDATA[Oh]]></surname>
<given-names><![CDATA[KH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical and genetic characteristics of korean autosomal dominant polycystic kidney disease patients]]></article-title>
<source><![CDATA[Korean J Intern Med]]></source>
<year>2021</year>
<volume>36</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>767-79</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>[7]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[VE]]></given-names>
</name>
<name>
<surname><![CDATA[Somlo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Besse]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Large deletions in GANAB and SEC63 explain 2 cases of polycystic kidney and liver disease]]></article-title>
<source><![CDATA[Kidney Int Rep]]></source>
<year>2020</year>
<volume>5</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>727-31</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>[8]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camargo]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Herrera]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Yomayusa-González]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ibañez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Valbuena- García]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autosomal dominant polycystic kidney disease in Colombia]]></article-title>
<source><![CDATA[BMC Nephrol]]></source>
<year>2023</year>
<volume>24</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>211</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>[9]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernandes Nunes]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Milani]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Benck Porsch]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bertolin Rossato]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bastos Mattos]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Roisenberg]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frequency and clinical profile of patients with polycystic kidney disease in southern Brazil]]></article-title>
<source><![CDATA[Ren Fail]]></source>
<year>2008</year>
<volume>30</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>169-73</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>[10]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barnawi]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Attar]]></surname>
<given-names><![CDATA[RZ]]></given-names>
</name>
<name>
<surname><![CDATA[Alfaer]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Safdar]]></surname>
<given-names><![CDATA[OY.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is the light at the end of the tunnel nigh? A review of ADPKD focusing on the burden of disease and tolvaptán as a new treatment]]></article-title>
<source><![CDATA[Int J Nephrol Renovasc Dis]]></source>
<year>2018</year>
<volume>11</volume>
<page-range>53-67</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>[11]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rastogi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ameen]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Baghdadi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Shaffer]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Nobakht]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kamgar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autosomal dominant polycystic kidney disease: updated perspectives]]></article-title>
<source><![CDATA[Ther Clin Risk Manag]]></source>
<year>2019</year>
<volume>15</volume>
<page-range>1041-52</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>[12]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Radhakrishnan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Duriseti]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Chebib]]></surname>
<given-names><![CDATA[FT.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options]]></article-title>
<source><![CDATA[Kidney Res Clin Pract]]></source>
<year>2022</year>
<volume>41</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>422-31</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>[13]</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[VE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Polycystic kidney disease, autosomal dominant]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Adam]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Feldman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mirzaa]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[ra]]></surname>
<given-names><![CDATA[Pagon]]></given-names>
</name>
<name>
<surname><![CDATA[Wallace]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Amemiya]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[GeneReviews]]></source>
<year>2022</year>
<page-range>5-57</page-range><publisher-loc><![CDATA[Seattle, Estados Unidos ]]></publisher-loc>
<publisher-name><![CDATA[University of Washington]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>[14]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vasileva]]></surname>
<given-names><![CDATA[VY]]></given-names>
</name>
<name>
<surname><![CDATA[Sultanova]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Sudarikova]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[Ilatovskaya]]></surname>
<given-names><![CDATA[DV.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insights into the molecular mechanisms ofpolycystic kidney diseases]]></article-title>
<source><![CDATA[Front Physiol]]></source>
<year>2021</year>
<volume>12</volume>
<page-range>693130</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>[15]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montaña]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Patiño]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Larrate]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Zambrano]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lozano]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Actualización en enfermedad renal poliquística]]></article-title>
<source><![CDATA[Rev Fac Med]]></source>
<year>2018</year>
<volume>66</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>107-16</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>[16]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cornec-Le Gall]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Blais]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Irazabal]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Devuyst]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Gansevoort]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[Perrone]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial]]></article-title>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2018</year>
<volume>33</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>645-52</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>[17]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kashyap S]]></surname>
<given-names><![CDATA[Hein KZ]]></given-names>
</name>
<name>
<surname><![CDATA[Chini CC]]></surname>
<given-names><![CDATA[LikaJ]]></given-names>
</name>
<name>
<surname><![CDATA[Warner GM]]></surname>
<given-names><![CDATA[Bale LK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metalloproteinase PAPP-A regulation of IGF-1 contributes to polycystic kidney disease pathogenesis]]></article-title>
<source><![CDATA[JCI Insight]]></source>
<year>2020</year>
<volume>5</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B18">
<label>[18]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carullo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Zicarelli]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Casarella]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nicotera]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Castagna]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Urso]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Retarding progression of chronic kidney disease in autosomal dominant polycystic kidney disease with metformin and other therapies: an update of new insights]]></article-title>
<source><![CDATA[Int J Gen Med]]></source>
<year>2021</year>
<volume>14</volume>
<page-range>5993-6000</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>[19]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bitarafan]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Garshasbi]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular genetic analysis ofpolycystic kidney disease 1 and polycystic kidney disease 2 mutations in pedigrees with autosomal dominant polycystic kidney disease]]></article-title>
<source><![CDATA[J Res Med Sci]]></source>
<year>2019</year>
<volume>24</volume>
<page-range>44</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>[20]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lai]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mangiulli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Perrotta]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Di Lazzaro Giraldi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Testorio]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rosato]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reduction in heart rate variability in autosomal dominant polycystic kidney disease]]></article-title>
<source><![CDATA[Kidney Blood Press Res]]></source>
<year>2019</year>
<volume>44</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1142-8</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>[21]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kuo]]></surname>
<given-names><![CDATA[IY]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[AB.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Polycystins, ADPKD, and Cardiovascular Disease]]></article-title>
<source><![CDATA[Kidney Int Rep]]></source>
<year>2019</year>
<volume>5</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>396-406</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>[22]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mei]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Xue]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[SQ]]></given-names>
</name>
<name>
<surname><![CDATA[Dai]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Executive summary: clinical practice guideline for autosomal dominant polycystic kidney disease in China]]></article-title>
<source><![CDATA[Kidney Dis]]></source>
<year>2020</year>
<volume>6</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>144-9</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>[23]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fukasawa]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kaneko]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Niwa]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Yasuda]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kumagai]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Furuya]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carbohydrate antigen 19-9 is significantly elevated in autosomal dominant polycystic kidney disease]]></article-title>
<source><![CDATA[Nephrology]]></source>
<year>2018</year>
<volume>23</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>210-6</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>[24]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Laecke]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Van Biesen]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Novel non-cystic features ofpolycystic kidney disease: Having new eyes or seeking new landscapes]]></article-title>
<source><![CDATA[Clin Kidney J]]></source>
<year>2021</year>
<volume>14</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>746-55</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>[25]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical manifestation, management and prognosis of acute myocardial infarction in autosomal dominant polycystic kidney disease]]></article-title>
<source><![CDATA[Kidney Blood Press Res]]></source>
<year>2018</year>
<volume>43</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1806-12</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>[26]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ecder]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Schrier]]></surname>
<given-names><![CDATA[RW.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects]]></article-title>
<source><![CDATA[J Am Soc Nephrol]]></source>
<year>2001</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>194-200</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>[27]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kalatharan]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Welk]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Nash]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Dixon]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
<name>
<surname><![CDATA[Slater]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pei]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk of hospital encounters with kidney stones in autosomal dominant polycystic kidney disease: a cohort study]]></article-title>
<source><![CDATA[Can J Kidney Health Dis]]></source>
<year>2021</year>
<volume>8</volume>
<page-range>20543581211000227</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>[28]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Laecke]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kerre]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Nagler]]></surname>
<given-names><![CDATA[EV]]></given-names>
</name>
<name>
<surname><![CDATA[Maes]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Caluwe]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Schepers]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hereditary polycys-tic kidney disease is characterized by lymphopenia across all stages ofkidney dysfunction: an observational study]]></article-title>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2018</year>
<volume>33</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>489-96</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>[29]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Banerjee]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chandna]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Jayasena]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Farrington]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Leucopenia in adult polycystic kidney disease patients on haemodialysis]]></article-title>
<source><![CDATA[Nephron]]></source>
<year>2002</year>
<volume>91</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>175-6</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>[30]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Férnandez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hortal]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Vega]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Plaza]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Palop]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anemia in dialysis: its relation to acquired cystic kidney disease and serum levels oferythropoietin]]></article-title>
<source><![CDATA[Am JNephrol]]></source>
<year>1991</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>12-5</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>[31]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eckardt]]></surname>
<given-names><![CDATA[KU]]></given-names>
</name>
<name>
<surname><![CDATA[Möllmann]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Neumann]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Brunkhorst]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Burger]]></surname>
<given-names><![CDATA[HU]]></given-names>
</name>
<name>
<surname><![CDATA[Lonnemann]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Erythropoietin in polycystic kidneys]]></article-title>
<source><![CDATA[J Clin Invest]]></source>
<year>1989</year>
<volume>84</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1160-6</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>[32]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Chuang]]></surname>
<given-names><![CDATA[YW]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[CK]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk of cancer in patients with polycystic kidney disease: a propensity-score matched analysis ofa nationwide, population-based cohort study]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2016</year>
<volume>17</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1419-25</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>[33]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mei]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The association between autosomal dominant polycystic kidney disease and cancer]]></article-title>
<source><![CDATA[Int Urol Nephrol]]></source>
<year>2019</year>
<volume>51</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>93-100</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>[34]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moua]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Zand]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hartman]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Hartman]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
<name>
<surname><![CDATA[Qin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Peikert]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiologic and clinical bronchiectasis associated with autosomal dominant polycystic kidney disease]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2014</year>
<volume>9</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B35">
<label>[35]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caillard]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Eprinchard]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Perrin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Braun]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Heibel]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Moreau]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence and risk factors of glucose metabolism disorders in kidney transplant recipients role ofsystematic screening by oral glucose tolerance test]]></article-title>
<source><![CDATA[Transplantation]]></source>
<year>2011</year>
<volume>91</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>757-64</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>[36]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheungpasitporn]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Thongprayoon]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Vijayvargiya]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Anthanont]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Erickson]]></surname>
<given-names><![CDATA[SB.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The risk for new-onset diabetes mellitus after kidney transplantation in patients with autosomal dominant polycystic kidney disease a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Can JDiabetes]]></source>
<year>2016</year>
<volume>40</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>521-8</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>[37]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Evenepoel]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Claes]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Cavalier]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Meijers]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Stenvinkel]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Behets]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A distinct bone phenotype in ADPKD patients with end-stage renal disease]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2019</year>
<volume>95</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>412-9</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>[38]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nowak]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Murray]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[You]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Gitomer]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Brosnahan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Abebe]]></surname>
<given-names><![CDATA[KZ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pain and obesity in autosomal dominant polycystic kidney disease: a post hoc analysis ofthe halt progression of polycystic kidney disease (HALT-PKD) studies]]></article-title>
<source><![CDATA[Kidney Med]]></source>
<year>2021</year>
<volume>3</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>536-45</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>[39]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pijl]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Glaudemans]]></surname>
<given-names><![CDATA[AWJM]]></given-names>
</name>
<name>
<surname><![CDATA[Slart]]></surname>
<given-names><![CDATA[RHJA]]></given-names>
</name>
<name>
<surname><![CDATA[Kwee]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[18F-FDG PET/CT in Autosomal Dominant Polycystic Kidney Disease Patients with Suspected Cyst Infection]]></article-title>
<source><![CDATA[J Nucl Med]]></source>
<year>2018</year>
<volume>59</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1734-41</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>[40]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Masui]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Wajima]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Aketa]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characteristics of the ruptured intracranial cerebral aneurysms in patients with autosomal dominant polycystic kidney disease (ADPKD) and review of literature]]></article-title>
<source><![CDATA[Interdiscip Neurosurg]]></source>
<year>2020</year>
<volume>22</volume>
</nlm-citation>
</ref>
<ref id="B41">
<label>[41]</label><nlm-citation citation-type="book">
<collab>University of Oxford</collab>
<source><![CDATA[OCEBM Levels of Evidence]]></source>
<year>2023</year>
<publisher-name><![CDATA[Centre for evidence-Based Medicine]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B42">
<label>[42]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Molnar]]></surname>
<given-names><![CDATA[AO]]></given-names>
</name>
<name>
<surname><![CDATA[Barua]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Konvalinka]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schick-Makaroff]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patient engagement in kidney research opportunities and challenges ahead]]></article-title>
<source><![CDATA[Can J Kidney Health Dis]]></source>
<year>2017</year>
<volume>4</volume>
<page-range>2054358117740583</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>[43]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soroka]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Alam]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bevilacqua]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Girard]]></surname>
<given-names><![CDATA[LP]]></given-names>
</name>
<name>
<surname><![CDATA[Komenda]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Loertscher]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Updated Canadian expert consensus on assessing risk of disease progression and pharmacological management of autosomal dominant polycystic kidney disease]]></article-title>
<source><![CDATA[Can J Kidney Health Dis]]></source>
<year>2018</year>
<volume>5</volume>
<page-range>2054358118801589</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>[44]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soroka]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Alam]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bevilacqua]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Girard]]></surname>
<given-names><![CDATA[LP]]></given-names>
</name>
<name>
<surname><![CDATA[Komenda]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Loertscher]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessing risk of disease progression and pharmacological management of autosomal dominant polycystic kidney disease: a canadian expert consensus]]></article-title>
<source><![CDATA[Can J Kidney Health Dis]]></source>
<year>2017</year>
<volume>4</volume>
<page-range>2054358117695784</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>[45]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pei]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Hwang]]></surname>
<given-names><![CDATA[YH]]></given-names>
</name>
<name>
<surname><![CDATA[Conklin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sundsbak]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Heyer]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Imaging-based diagnosis ofautosomal dominant polycystic kidney disease]]></article-title>
<source><![CDATA[J Am Soc Nephrol]]></source>
<year>2015</year>
<volume>26</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>746-53</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>[46]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pei]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Obaji]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dupuis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Paterson]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Magistroni]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Dicks]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Unified criteria for ultrasonographic diagnosis of ADPKD]]></article-title>
<source><![CDATA[J Am Soc Nephrol]]></source>
<year>2009</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>205-12</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>[47]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ars]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bernis]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fraga]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Martins]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ortiz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Spanish guidelines for the management of autosomal dominant polycystic kidney disease]]></article-title>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2014</year>
<volume>29</volume>
<numero>^s4</numero>
<issue>^s4</issue>
<supplement>4</supplement>
<page-range>iv95-105</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>[48]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Audrézet]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Cornec-Le Gall]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Redon]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Quéré]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Creff]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autosomal dominant polycystic kidney disease: comprehensive mutation analysis of PKD1 and PKD2 in 700 unrelated patients]]></article-title>
<source><![CDATA[Hum Mutat]]></source>
<year>2012</year>
<volume>33</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1239-50</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>[49]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torra]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Badenas]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Darnell]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nicolau]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Volpini]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Revert]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Linkage, clinical features, and prognosis of autosomal dominant polycystic kidney disease types 1 and 2]]></article-title>
<source><![CDATA[J Am Soc Nephrol]]></source>
<year>1996</year>
<volume>7</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2142-51</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>[50]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Consugar]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
<name>
<surname><![CDATA[Lundquist]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Rossetti]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kubly]]></surname>
<given-names><![CDATA[VJ]]></given-names>
</name>
<name>
<surname><![CDATA[Walker]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2008</year>
<volume>74</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1468-79</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>[51]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bullich]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Domingo-Gallego]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vargas]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lorente-Grandoso]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Furlano]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A kidney-disease gene panel allows a comprehensive genetic diagnosis of cystic and glomerular inherited kidney diseases]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2018</year>
<volume>94</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>363-71</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>[52]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vujic]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Heyer]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Ars]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hopp]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Markoff]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Orndal]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incompletely penetrant PKD1 alleles mimic the renal manifestations of ARPKD]]></article-title>
<source><![CDATA[J Am Soc Nephrol]]></source>
<year>2010</year>
<volume>21</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1097-102</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>[53]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rossetti]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kubly]]></surname>
<given-names><![CDATA[VJ]]></given-names>
</name>
<name>
<surname><![CDATA[Consugar]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Hopp]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Roy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Horsley]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2009</year>
<volume>75</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>848-55</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>[54]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Le Gall]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Audrézet]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Rousseau]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hourmant]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Renaudineau]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Charasse]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease]]></article-title>
<source><![CDATA[J Am Soc Nephrol]]></source>
<year>2016</year>
<volume>27</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>942-51</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>[55]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sekine]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hidaka]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Moriyama]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Shikida]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Shimazu]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ishikawa]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cystic kidney diseases that require a differential diagnosis from autosomal dominant polycystic kidney disease (ADPKD)]]></article-title>
<source><![CDATA[J Clin Med]]></source>
<year>2022</year>
<volume>11</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>6528</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>[56]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schrier]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Brosnahan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cadnapaphornchai]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Chonchol]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Friend]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Gitomer]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predictors of autosomal dominant polycystic kidney disease progression]]></article-title>
<source><![CDATA[J Am Soc Nephrol]]></source>
<year>2014</year>
<volume>25</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2399-418</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>[57]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reiterová]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tesar]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autosomal dominant polycystic kidney disease: from pathophysiology of cystogenesis to advances in the treatment]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2022</year>
<volume>23</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>3317</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>[58]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cornec-Le Gall]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Olson]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Besse]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Heyer]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Gainullin]]></surname>
<given-names><![CDATA[VG]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease]]></article-title>
<source><![CDATA[Am J Hum Genet]]></source>
<year>2018</year>
<volume>102</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>832-44</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>[59]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chebib]]></surname>
<given-names><![CDATA[FT]]></given-names>
</name>
<name>
<surname><![CDATA[Perrone]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Dahl]]></surname>
<given-names><![CDATA[NK]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Mrug]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A practical guide for treatment of rapidly progressive ADPKD with tolvaptán]]></article-title>
<source><![CDATA[J Am Soc Nephrol]]></source>
<year>2018</year>
<volume>29</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2458-70</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>[60]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cornec-Le Gall]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Audrézet]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Hourmant]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Morin]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Perrichot]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Type of PKD1 mutation influences renal outcome in ADPKD]]></article-title>
<source><![CDATA[J Am Soc Nephrol]]></source>
<year>2013</year>
<volume>24</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1006-13</page-range></nlm-citation>
</ref>
<ref id="B61">
<label>[61]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Magistroni]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Andrew]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gabow]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genotype-renal function correlation in type 2 autosomal dominant polycystic kidney disease]]></article-title>
<source><![CDATA[J Am Soc Nephrol]]></source>
<year>2003</year>
<volume>14</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1164-74</page-range></nlm-citation>
</ref>
<ref id="B62">
<label>[62]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fick-Brosnahan]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Tran]]></surname>
<given-names><![CDATA[ZV]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Strain]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Gabow]]></surname>
<given-names><![CDATA[PA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Progression of autosomal-dominant polycystic kidney disease in children]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2001</year>
<volume>59</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1654-62</page-range></nlm-citation>
</ref>
<ref id="B63">
<label>[63]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pei]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Lan]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia-Gonzalez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Dicks]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A missense mutation in PKD1 attenuates the severity of renal disease]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2012</year>
<volume>81</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>412-7</page-range></nlm-citation>
</ref>
<ref id="B64">
<label>[64]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez-Oller]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Torra]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Badenas]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Milà]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Darnell]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Influence of the ACE gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease]]></article-title>
<source><![CDATA[Am J Kidney Dis]]></source>
<year>1999</year>
<volume>34</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>273-8</page-range></nlm-citation>
</ref>
<ref id="B65">
<label>[65]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Casteleijn]]></surname>
<given-names><![CDATA[NF]]></given-names>
</name>
<name>
<surname><![CDATA[Zittema]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bakker]]></surname>
<given-names><![CDATA[SJL]]></given-names>
</name>
<name>
<surname><![CDATA[Boertien]]></surname>
<given-names><![CDATA[WE]]></given-names>
</name>
<name>
<surname><![CDATA[Gaillard]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Meijer]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Urine and plasma osmolality in patients with autosomal dominant polycystic kidney disease: reliable indicators of vasopressin activity and disease prognosis?]]></article-title>
<source><![CDATA[Am J Nephrol]]></source>
<year>2015</year>
<volume>41</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>248-56</page-range></nlm-citation>
</ref>
<ref id="B66">
<label>[66]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Segarra-Medrano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Agraz]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Vilaprinyó]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chamoun]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Jatem]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association between urinary biomarkers and disease progression in adults with autosomal dominant polycystic kidney disease]]></article-title>
<source><![CDATA[Clin Kidney J.]]></source>
<year>2020</year>
<volume>13</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>607-12</page-range></nlm-citation>
</ref>
<ref id="B67">
<label>[67]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hallows]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Althouse]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Saitta]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Abebe]]></surname>
<given-names><![CDATA[KZ]]></given-names>
</name>
<name>
<surname><![CDATA[Bae]]></surname>
<given-names><![CDATA[KT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association ofbaseline urinary metabolic biomarkers with ADPKD severity in TAME-PKD clinical trial participants]]></article-title>
<source><![CDATA[Kidney360]]></source>
<year>2021</year>
<volume>2</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>795-808</page-range></nlm-citation>
</ref>
<ref id="B68">
<label>[68]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liebau]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Mekahli]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Perrone]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Soyfer]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Fedeles]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Polycystic kidney disease drug development: a conference report]]></article-title>
<source><![CDATA[Kidney Med]]></source>
<year>2022</year>
<volume>5</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>100596</page-range></nlm-citation>
</ref>
<ref id="B69">
<label>[69]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Messchendorp]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Meijer]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Visser]]></surname>
<given-names><![CDATA[FW]]></given-names>
</name>
<name>
<surname><![CDATA[Engels]]></surname>
<given-names><![CDATA[GE]]></given-names>
</name>
<name>
<surname><![CDATA[Kappert]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Losekoot]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rapid progression of autosomal dominant polycystic kidney disease: urinary biomarkers as predictors]]></article-title>
<source><![CDATA[Am J Nephrol]]></source>
<year>2019</year>
<volume>50</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>375-85</page-range></nlm-citation>
</ref>
<ref id="B70">
<label>[70]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[VE]]></given-names>
</name>
<name>
<surname><![CDATA[Grantham]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Mrug]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bae]]></surname>
<given-names><![CDATA[KT]]></given-names>
</name>
<name>
<surname><![CDATA[King]]></surname>
<given-names><![CDATA[BF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease]]></article-title>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2011</year>
<volume>6</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>640-7</page-range></nlm-citation>
</ref>
<ref id="B71">
<label>[71]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Helal]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[McFann]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Reed]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[XD]]></given-names>
</name>
<name>
<surname><![CDATA[Schrier]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Fick-Brosnahan]]></surname>
<given-names><![CDATA[GM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease]]></article-title>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2013</year>
<volume>28</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>380-5</page-range></nlm-citation>
</ref>
<ref id="B72">
<label>[72]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brosnahan]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[You]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Gitomer]]></surname>
<given-names><![CDATA[BY]]></given-names>
</name>
<name>
<surname><![CDATA[Chonchol]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serum uric acid and progression of autosomal dominant polycystic kidney disease: results from the HALT PKD Trials]]></article-title>
<source><![CDATA[Curr Hypertens Rev]]></source>
<year>2021</year>
<volume>17</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>228-37</page-range></nlm-citation>
</ref>
<ref id="B73">
<label>[73]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Irazabal]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Rangel]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bergstralh]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Osborn]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Harmon]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sundsbak]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials]]></article-title>
<source><![CDATA[J Am Soc Nephrol]]></source>
<year>2015</year>
<volume>26</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>160-72</page-range></nlm-citation>
</ref>
<ref id="B74">
<label>[74]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Devuyst]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Eckardt]]></surname>
<given-names><![CDATA[KU]]></given-names>
</name>
<name>
<surname><![CDATA[Gansevoort]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Horie]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2015</year>
<volume>88</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>17-27</page-range></nlm-citation>
</ref>
<ref id="B75">
<label>[75]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grantham]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[VE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The importance of total kidney volume in evaluating progression of polycystic kidney disease]]></article-title>
<source><![CDATA[Nat Rev Nephrol]]></source>
<year>2016</year>
<volume>12</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>667-77</page-range></nlm-citation>
</ref>
<ref id="B76">
<label>[76]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Müller]]></surname>
<given-names><![CDATA[RU]]></given-names>
</name>
<name>
<surname><![CDATA[Messchendorp]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Birn]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Capasso]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cornec-Le Gall]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Devuyst]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An update on the use of tolvaptán for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International]]></article-title>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2022</year>
<volume>37</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>825-39</page-range></nlm-citation>
</ref>
<ref id="B77">
<label>[77]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Horie]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mochizuki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Muto]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hanaoka]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Fukushima]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Narita]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evidence-based clinical practice guidelines for polycystic kidney disease 2014]]></article-title>
<source><![CDATA[Clin Exp Nephrol]]></source>
<year>2016</year>
<volume>20</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>493-509</page-range></nlm-citation>
</ref>
<ref id="B78">
<label>[78]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Girardat-Rotar]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Braun]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Puhan]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Abraham]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Serra]]></surname>
<given-names><![CDATA[AL.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Temporal and geographical external validation study and extension of the Mayo Clinic prediction model to predict eGFR in the younger population of Swiss ADPKD patients]]></article-title>
<source><![CDATA[BMC Nephrol]]></source>
<year>2017</year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>241</page-range></nlm-citation>
</ref>
<ref id="B79">
<label>[79]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rangan]]></surname>
<given-names><![CDATA[GK]]></given-names>
</name>
<name>
<surname><![CDATA[Alexander]]></surname>
<given-names><![CDATA[SI]]></given-names>
</name>
<name>
<surname><![CDATA[Campbell]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Dexter]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[VW]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez-Vargas]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[KHA-CARI guideline recommendations for the diagnosis and management of autosomal dominant polycystic kidney disease]]></article-title>
<source><![CDATA[Nephrology]]></source>
<year>2016</year>
<volume>21</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>705-16</page-range></nlm-citation>
</ref>
<ref id="B80">
<label>[80]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gansevoort]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[Meijer]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Czerwiec]]></surname>
<given-names><![CDATA[FS]]></given-names>
</name>
<name>
<surname><![CDATA[Devuyst]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Grantham]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Albuminuria and tolvaptán in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial]]></article-title>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2016</year>
<volume>31</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1887-94</page-range></nlm-citation>
</ref>
<ref id="B81">
<label>[81]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nobakht]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Hanna]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Baghdadi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ameen]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Arman]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Nobahkt]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advances in autosomal dominant polycystic kidney disease: a clinical review]]></article-title>
<source><![CDATA[Kidney Med]]></source>
<year>2020</year>
<volume>2</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>196-208</page-range></nlm-citation>
</ref>
<ref id="B82">
<label>[82]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quiroga]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Torra]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dietary aspects and drug-related side effects in autosomal dominant polycystic kidney disease progression]]></article-title>
<source><![CDATA[Nutrients]]></source>
<year>2022</year>
<volume>14</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>4651</page-range></nlm-citation>
</ref>
<ref id="B83">
<label>[83]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kramers]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Koorevaar]]></surname>
<given-names><![CDATA[IW]]></given-names>
</name>
<name>
<surname><![CDATA[Drenth]]></surname>
<given-names><![CDATA[JPH]]></given-names>
</name>
<name>
<surname><![CDATA[de Fijter]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Gomes Neto]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Peters]]></surname>
<given-names><![CDATA[DJM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2020</year>
<volume>98</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>989-98</page-range></nlm-citation>
</ref>
<ref id="B84">
<label>[84]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[VE]]></given-names>
</name>
<name>
<surname><![CDATA[Abebe]]></surname>
<given-names><![CDATA[KZ]]></given-names>
</name>
<name>
<surname><![CDATA[Schrier]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Perrone]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2017</year>
<volume>91</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>493-500</page-range></nlm-citation>
</ref>
<ref id="B85">
<label>[85]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McBride]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Wilkinson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Jesudason]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of autosomal dominant polycystic kidney disease (ADPKD) during pregnancy risks and challenges]]></article-title>
<source><![CDATA[Int J Womens Health]]></source>
<year>2020</year>
<volume>12</volume>
<page-range>409-22</page-range></nlm-citation>
</ref>
<ref id="B86">
<label>[86]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bulent Gul]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Yildiz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sag]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Oruc]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ersoy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gullulu]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effect of smoking on endothelial dysfunction in autosomal dominant polycystic kidney disease patients with preserved renal function]]></article-title>
<source><![CDATA[Ren Fail]]></source>
<year>2021</year>
<volume>43</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1124-9</page-range></nlm-citation>
</ref>
<ref id="B87">
<label>[87]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shoaf]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Ouyang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sergeyeva]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Estilo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Leung]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A post hoc analysis of statin use in tolvaptán autosomal dominant polycystic kidney disease pivotal trials]]></article-title>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2020</year>
<volume>15</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>643-50</page-range></nlm-citation>
</ref>
<ref id="B88">
<label>[88]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Trott]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Gao]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Weiss]]></surname>
<given-names><![CDATA[RH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course]]></article-title>
<source><![CDATA[BMC Nephrol]]></source>
<year>2019</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>66</page-range></nlm-citation>
</ref>
<ref id="B89">
<label>[89]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[VE]]></given-names>
</name>
<name>
<surname><![CDATA[Abebe]]></surname>
<given-names><![CDATA[KZ]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Schrier]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Braun]]></surname>
<given-names><![CDATA[WE]]></given-names>
</name>
<name>
<surname><![CDATA[Steinman]]></surname>
<given-names><![CDATA[TI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Angiotensin blockade in late autosomal dominant polycystic kidney disease]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2014</year>
<volume>371</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>2267-76</page-range></nlm-citation>
</ref>
<ref id="B90">
<label>[90]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[JX]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[VE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autosomal dominant polycystic kidney disease therapies on the horizon]]></article-title>
<source><![CDATA[Adv Kidney Dis Health]]></source>
<year>2023</year>
<volume>30</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>245-60</page-range></nlm-citation>
</ref>
<ref id="B91">
<label>[91]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Horie]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Muto]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kawano]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Okada]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Shibasaki]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Nakajima]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptán treatment in patients with autosomal dominant polycystic kidney disease]]></article-title>
<source><![CDATA[Clin Exp Nephrol]]></source>
<year>2021</year>
<volume>25</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>467-78</page-range></nlm-citation>
</ref>
<ref id="B92">
<label>[92]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nakatani]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sakata]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Suna]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Usami]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Matsumoto]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Shimizu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence, predictors, and subsequent mortality risk of recurrent myocardial infarction in patients following discharge for acute myocardial infarction]]></article-title>
<source><![CDATA[Circ J]]></source>
<year>2013</year>
<volume>77</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>439-46</page-range></nlm-citation>
</ref>
<ref id="B93">
<label>[93]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mochizuki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Muto]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Miyake]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and efficacy of Tolvaptán in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillance]]></article-title>
<source><![CDATA[Clin Exp Nephrol]]></source>
<year>2021</year>
<volume>25</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1231-9</page-range></nlm-citation>
</ref>
<ref id="B94">
<label>[94]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[VE]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Devuyst]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Gansevoort]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[Perrone]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Dandurand]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptán in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial]]></article-title>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2018</year>
<volume>33</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>477-89</page-range></nlm-citation>
</ref>
<ref id="B95">
<label>[95]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Gong]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of tolvap-tán versus placebo in the treatment of patients with autosomal dominant polycystic kidney disease: a meta-analysis]]></article-title>
<source><![CDATA[Int Urol Nephrol]]></source>
<year>2022</year>
<volume>55</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>631-40</page-range></nlm-citation>
</ref>
<ref id="B96">
<label>[96]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[VE]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Devuyst]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Gansevoort]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[Perrone]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Koch]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tolvaptán in later-stage autosomal dominant polycystic kidney disease]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2017</year>
<volume>377</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>1930-42</page-range></nlm-citation>
</ref>
<ref id="B97">
<label>[97]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chebib]]></surname>
<given-names><![CDATA[FT]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Garbinsky]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Davenport]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Nunna]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Oberdhan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tolvaptán and kidney function decline in older individuals with autosomal dominant polycystic kidney disease: a pooled analysis of randomized clinical trials and observational studies]]></article-title>
<source><![CDATA[Kidney Med]]></source>
<year>2023</year>
<volume>5</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>100639</page-range></nlm-citation>
</ref>
<ref id="B98">
<label>[98]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Dong]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The safety and efficacy of tolvaptán in the treatment of patients with autosomal dominant polycystic kidney disease: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Nefrologia]]></source>
<year>2023</year>
<volume>43</volume>
<numero>6</numero>
<edition>Engl</edition>
<issue>6</issue>
<page-range>731-41</page-range></nlm-citation>
</ref>
<ref id="B99">
<label>[99]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muto]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Okada]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Yasuda]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tsubouchi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Nakajima]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Horie]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term safety profile of tolvaptán in autosomal dominant polycystic kidney disease patients: TEMPO extension Japan trial]]></article-title>
<source><![CDATA[Drug Healthc Patient Saf]]></source>
<year>2017</year>
<volume>9</volume>
<page-range>93-104</page-range></nlm-citation>
</ref>
<ref id="B100">
<label>[100]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Higashihara]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Nutahara]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Itoh]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Okegawa]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Tambo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yamaguchi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term outcomes of longitudinal efficacy study with tolvaptán in ADPKD]]></article-title>
<source><![CDATA[Kidney Int Rep]]></source>
<year>2022</year>
<volume>7</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>270-81</page-range></nlm-citation>
</ref>
<ref id="B101">
<label>[101]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gansevoort]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[Arici]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Benzing]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Birn]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Capasso]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Covic]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recommendations for the use of tolvaptán in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice]]></article-title>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2016</year>
<volume>31</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>337-48</page-range></nlm-citation>
</ref>
<ref id="B102">
<label>[102]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[VE]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Devuyst]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Gansevoort]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[Grantham]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Higashihara]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tolvaptán in patients with autosomal dominant polycystic kidney disease]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2012</year>
<volume>367</volume>
<numero>25</numero>
<issue>25</issue>
<page-range>2407-18</page-range></nlm-citation>
</ref>
<ref id="B103">
<label>[103]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Devuyst]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Shoaf]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Czerwiec]]></surname>
<given-names><![CDATA[FS]]></given-names>
</name>
<name>
<surname><![CDATA[Blais]]></surname>
<given-names><![CDATA[JD.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tolerability of aquaretic-related symptoms following tolvaptán for autosomal dominant polycystic kidney disease: results from TEMPO 3:4]]></article-title>
<source><![CDATA[Kidney Int Rep]]></source>
<year>2017</year>
<volume>2</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1132-40</page-range></nlm-citation>
</ref>
<ref id="B104">
<label>[104]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anderegg]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Dhayat]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Sommer]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Semmo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Huynh-Do]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Vogt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quality of life in autosomal dominant polycystic kidney disease patients treated with tolvaptán]]></article-title>
<source><![CDATA[Kidney Med]]></source>
<year>2020</year>
<volume>2</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>162-71</page-range></nlm-citation>
</ref>
<ref id="B105">
<label>[105]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[VE]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Devuyst]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Gansevoort]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[Perrone]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multicenter study of long-term safety of tolvaptán in later-stage autosomal dominant polycystic kidney disease]]></article-title>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2020</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>48-58</page-range></nlm-citation>
</ref>
<ref id="B106">
<label>[106]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Merino Bueno]]></surname>
<given-names><![CDATA[MDC]]></given-names>
</name>
<name>
<surname><![CDATA[Sango Merino]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gallardo Pérez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rojo Alba]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz Zorrilla]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[de la Torre Fernández]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hepatotoxicity induced by tolvaptán: a case report]]></article-title>
<source><![CDATA[Nefrologia]]></source>
<year>2022</year>
<volume>42</volume>
<numero>6</numero>
<edition>Engl</edition>
<issue>6</issue>
<page-range>737-8</page-range></nlm-citation>
</ref>
<ref id="B107">
<label>[107]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alpers]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Hunt]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Freston]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[VE]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical pattern of tolvaptán-associated liver injury in trial participants with autosomal dominant polycystic kidney disease (ADPKD): an analysis of pivotal clinical trials]]></article-title>
<source><![CDATA[Am J Kidney Dis]]></source>
<year>2023</year>
<volume>81</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>281-293.e1</page-range></nlm-citation>
</ref>
<ref id="B108">
<label>[108]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kramers]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[van Gastel]]></surname>
<given-names><![CDATA[MDA]]></given-names>
</name>
<name>
<surname><![CDATA[Meijer]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gansevoort]]></surname>
<given-names><![CDATA[RT.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Case report: a thiazide diuretic to treat polyuria induced by tolvaptán]]></article-title>
<source><![CDATA[BMC Nephrol]]></source>
<year>2018</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>157</page-range></nlm-citation>
</ref>
<ref id="B109">
<label>[109]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sans-Atxer]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Joly]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tolvaptán in the treatment of autosomal dominant polycystic kidney disease: Patient selection and special considerations]]></article-title>
<source><![CDATA[Int J Nephrol Renovasc Dis]]></source>
<year>2018</year>
<volume>11</volume>
<page-range>41-51</page-range></nlm-citation>
</ref>
<ref id="B110">
<label>[110]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Franca Gois]]></surname>
<given-names><![CDATA[PH]]></given-names>
</name>
<name>
<surname><![CDATA[Butcher]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
<name>
<surname><![CDATA[Ta]]></surname>
<given-names><![CDATA[MHT]]></given-names>
</name>
<name>
<surname><![CDATA[Van Wyk]]></surname>
<given-names><![CDATA[GW.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment persistence to tolvaptán in patients with autosomal dominant polycystic kidney disease: a secondary use of data analysis of patients in the IMADJIN® dataset]]></article-title>
<source><![CDATA[BMC Nephrol]]></source>
<year>2021</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>400</page-range></nlm-citation>
</ref>
<ref id="B111">
<label>[111]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tsukamoto]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Urate]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yamada]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Azushima]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Yamaji]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kinguchi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative efficacy of pharmacological treatments for adults with autosomal dominant polycystic kidney disease: a systematic review and network meta-analysis of randomized controlled trials]]></article-title>
<source><![CDATA[Front Pharmacol]]></source>
<year>2022</year>
<volume>13</volume>
<page-range>885457</page-range></nlm-citation>
</ref>
<ref id="B112">
<label>[112]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caroli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Perico]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Perna]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Antiga]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Brambilla]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Pisani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of longac-ting somatostatin analogue on kidney and cyst growth in autosomal dominant polycys-tic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2013</year>
<volume>382</volume>
<numero>9903</numero>
<issue>9903</issue>
<page-range>1485-95</page-range></nlm-citation>
</ref>
<ref id="B113">
<label>[113]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meijer]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Visser]]></surname>
<given-names><![CDATA[FW]]></given-names>
</name>
<name>
<surname><![CDATA[van Aerts]]></surname>
<given-names><![CDATA[RMM]]></given-names>
</name>
<name>
<surname><![CDATA[Blijdorp]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Casteleijn]]></surname>
<given-names><![CDATA[NF]]></given-names>
</name>
<name>
<surname><![CDATA[D'Agnolo]]></surname>
<given-names><![CDATA[HMA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2018</year>
<volume>320</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>2010-9</page-range></nlm-citation>
</ref>
<ref id="B114">
<label>[114]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trillini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Caroli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Perico]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Remuzzi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Brambilla]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Villa]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of octreotide-long-acting release added-on tolvaptán in patients with autosomal dominant polycystic kid ney disease: pilot, randomized, placebo-controlled, cross-over trial]]></article-title>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2023</year>
<volume>18</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>223-33</page-range></nlm-citation>
</ref>
<ref id="B115">
<label>[115]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Higashihara]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Nutahara]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Okegawa]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Tanbo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mori]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Miyazaki]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety study of somatostatin analogue octreotide for autosomal dominant polycystic kidney disease in Japan]]></article-title>
<source><![CDATA[Clin Exp Nephrol]]></source>
<year>2015</year>
<volume>19</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>746-52</page-range></nlm-citation>
</ref>
<ref id="B116">
<label>[116]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruggenenti]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gentile]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Perico]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Perna]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Barcella]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Trillini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of siroli-mus on disease progression in patients with autosomal dominant polycystic kidney disease and CKD stages 3b-4]]></article-title>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2016</year>
<volume>11</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>785-94</page-range></nlm-citation>
</ref>
<ref id="B117">
<label>[117]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ji]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of mTOR inhibitor therapy in patients with early-stage autosomal dominant polycystic kidney disease: a meta-analysis of randomized controlled trials]]></article-title>
<source><![CDATA[Am J Med Sci]]></source>
<year>2012</year>
<volume>344</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>491-7</page-range></nlm-citation>
</ref>
<ref id="B118">
<label>[118]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perrone]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Abebe]]></surname>
<given-names><![CDATA[KZ]]></given-names>
</name>
<name>
<surname><![CDATA[Watnick]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Althouse]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Hallows]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Lalama]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD)]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2021</year>
<volume>100</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>684-96</page-range></nlm-citation>
</ref>
<ref id="B119">
<label>[119]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seliger]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Abebe]]></surname>
<given-names><![CDATA[KZ]]></given-names>
</name>
<name>
<surname><![CDATA[Hallows]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Miskulin]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Perrone]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Watnick]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Randomized clinical trial of metformin to treat autosomal dominant polycystic kidney disease]]></article-title>
<source><![CDATA[Am J Nephrol]]></source>
<year>2018</year>
<volume>47</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>352-60</page-range></nlm-citation>
</ref>
<ref id="B120">
<label>[120]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kramers]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Koorevaar]]></surname>
<given-names><![CDATA[IW]]></given-names>
</name>
<name>
<surname><![CDATA[van Gastel]]></surname>
<given-names><![CDATA[MDA]]></given-names>
</name>
<name>
<surname><![CDATA[van Goor]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hallows]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Heerspink]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of hydrochlorothiazide and metformin on aquaresis and nephroprotection by a vasopressin V2 receptor antagonist in ADPKD: a randomized crossover trial]]></article-title>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2022</year>
<volume>17</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>507-17</page-range></nlm-citation>
</ref>
<ref id="B121">
<label>[121]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gansevoort]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[Hariri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Minini]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ahn]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Horie]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Venglustat, a novel glucosylceramide synthase inhibitor, in patients at risk of rapidly progressing ADPKD: primary results of a double-blind, placebo-controlled, phase 2/3 randomized clinical trial]]></article-title>
<source><![CDATA[Am J Kidney Dis]]></source>
<year>2023</year>
<volume>81</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>517-27.e1</page-range></nlm-citation>
</ref>
<ref id="B122">
<label>[122]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perrone]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Hariri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Minini]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ahn]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Horie]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The STAGED- PKD 2-Stage adaptive study with a patient enrichment strategy and treatment effect modeling for improved study design efficiency in patients with ADPKD]]></article-title>
<source><![CDATA[Kidney Med]]></source>
<year>2022</year>
<volume>4</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>100538</page-range></nlm-citation>
</ref>
<ref id="B123">
<label>[123]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[VE]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Pirson]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autosomal dominant polycystic kidney disease]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2007</year>
<volume>369</volume>
<numero>9569</numero>
<issue>9569</issue>
<page-range>1287-301</page-range></nlm-citation>
</ref>
<ref id="B124">
<label>[124]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Willey]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Blais]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Krasa]]></surname>
<given-names><![CDATA[HB]]></given-names>
</name>
<name>
<surname><![CDATA[Makin]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Czerwiec]]></surname>
<given-names><![CDATA[FS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of autosomal dominant polycystic kidney disease in the European Union]]></article-title>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2017</year>
<volume>32</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1356-63</page-range></nlm-citation>
</ref>
<ref id="B125">
<label>[125]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Budhram]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Akbari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Biyani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Knoll]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Zimmerman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[End-Stage kidney disease in patients with autosomal dominant polycystic kidney disease: a 12-year study based on the Canadian organ replacement registry]]></article-title>
<source><![CDATA[Can J Kidney Health Dis]]></source>
<year>2018</year>
<volume>5</volume>
<page-range>2054358118778568</page-range></nlm-citation>
</ref>
<ref id="B126">
<label>[126]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sigogne]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kanagaratnam]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mora]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Pierre]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Petrache]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Marcus]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identification of the factors associated with intraperitoneal pressure in ADPKD patients treated with peritoneal dialysis]]></article-title>
<source><![CDATA[Kidney Int Rep]]></source>
<year>2020</year>
<volume>5</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1007-13</page-range></nlm-citation>
</ref>
<ref id="B127">
<label>[127]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dupont]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Kanagaratnam]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sigogne]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bechade]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lobbedez]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Portoles]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Outcome of polycystic kidney disease patients on peritoneal dialysis: systematic review of literature and meta-analysis]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2018</year>
<volume>13</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B128">
<label>[128]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[VE]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[PC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autosomal dominant polycystic kidney disease: the last 3 years]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2009</year>
<volume>76</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>149-68</page-range></nlm-citation>
</ref>
<ref id="B129">
<label>[129]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chebib]]></surname>
<given-names><![CDATA[FT]]></given-names>
</name>
<name>
<surname><![CDATA[Prieto]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Irazabal]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Kremers]]></surname>
<given-names><![CDATA[WK]]></given-names>
</name>
<name>
<surname><![CDATA[Dean]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Native neph-rectomy in renal transplant recipients with autosomal dominant polycystic kidney disease]]></article-title>
<source><![CDATA[Transplant Direct]]></source>
<year>2015</year>
<volume>1</volume>
<numero>10</numero>
<issue>10</issue>
</nlm-citation>
</ref>
<ref id="B130">
<label>[130]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[D'Souza]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Lau]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
<name>
<surname><![CDATA[Leslie]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Yao]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Staged versus concurrent native nephrectomy and renal transplantation in patients with autosomal dominant polycystic kidney disease: a systematic review]]></article-title>
<source><![CDATA[Transplant Rev]]></source>
<year>2022</year>
<volume>36</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>100652</page-range><publisher-loc><![CDATA[Orlando ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B131">
<label>[131]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ye]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Voss]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Athreya]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Volume reduction in enlarged kidneys in autosomal dominant polycystic kidney disease (ADPKD) prior to renal transplant with transcatheter arterial embolization (TAE): a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Cardiovasc Intervent Radiol]]></source>
<year>2018</year>
<volume>41</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>828-34</page-range></nlm-citation>
</ref>
<ref id="B132">
<label>[132]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Jeong]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Yuk]]></surname>
<given-names><![CDATA[HD]]></given-names>
</name>
<name>
<surname><![CDATA[Ku]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Kwak]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and feasibility of synchronous unilateral nephrectomy and contralateral heminephrectomy for extremely severe autosomal dominant polycystic kidney disease: techniques and outcome]]></article-title>
<source><![CDATA[Investig Clin Urol]]></source>
<year>2022</year>
<volume>63</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>341-9</page-range></nlm-citation>
</ref>
<ref id="B133">
<label>[133]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lanktree]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Haghighi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[di Bari]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Pei]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insights into autosomal dominant polycystic kidney disease from genetic studies]]></article-title>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2021</year>
<volume>16</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>790-9</page-range></nlm-citation>
</ref>
<ref id="B134">
<label>[134]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ravine]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gibson]]></surname>
<given-names><![CDATA[RN]]></given-names>
</name>
<name>
<surname><![CDATA[Walker]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Sheffield]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kincaid-Smith]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Danks]]></surname>
<given-names><![CDATA[DM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1994</year>
<volume>343</volume>
<numero>8901</numero>
<issue>8901</issue>
<page-range>824-7</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
